Floatz logo

Zofran

Immune System Diseases

UNC Lineberger Comprehensive Cancer CenterPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Immune System Diseases cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Indapta Therapeutics, INC.
Phase 2BB
Monomethyl Fumarate
National Cancer Institute (NCI)
Phase 2BB
Fludarabine
Indapta Therapeutics, INC.
Phase 2BB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BB
Strimvelis
Fondazione Telethon
Phase 4B

View all 33 →

Same molecule, other indications

Zofran is also rated in:

NauseaDormant
BBB
Indicative ·
73 / 100
View asset →
VomitingDormant
BBB
Indicative ·
73 / 100
View asset →
Non-Hodgkin's LymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →